MX2023012324A - Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. - Google Patents

Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.

Info

Publication number
MX2023012324A
MX2023012324A MX2023012324A MX2023012324A MX2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A
Authority
MX
Mexico
Prior art keywords
specific
charge distribution
igg molecule
chain pairing
electrostatic steering
Prior art date
Application number
MX2023012324A
Other languages
English (en)
Spanish (es)
Inventor
Zhulun Wang
Bram Estes
Fernando Garces
Danyang Gong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023012324A publication Critical patent/MX2023012324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023012324A 2021-04-20 2022-04-19 Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. MX2023012324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163177325P 2021-04-20 2021-04-20
PCT/US2022/025340 WO2022225921A1 (en) 2021-04-20 2022-04-19 Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly

Publications (1)

Publication Number Publication Date
MX2023012324A true MX2023012324A (es) 2023-10-30

Family

ID=81580206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012324A MX2023012324A (es) 2021-04-20 2022-04-19 Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.

Country Status (8)

Country Link
US (1) US20240182600A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326761A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515301A (cg-RX-API-DMAC7.html)
CN (1) CN117651714A (cg-RX-API-DMAC7.html)
AU (1) AU2022263406A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216559A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012324A (cg-RX-API-DMAC7.html)
WO (1) WO2022225921A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR134814A1 (es) * 2023-12-21 2026-04-15 Amgen Inc Mutaciones estabilizadoras de homodímeros para la producción de heterodímeros bicelulares

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
US9527927B2 (en) * 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2020264384A1 (en) * 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins

Also Published As

Publication number Publication date
JP2024515301A (ja) 2024-04-08
US20240182600A1 (en) 2024-06-06
EP4326761A1 (en) 2024-02-28
AU2022263406A1 (en) 2023-10-19
CA3216559A1 (en) 2022-10-27
CN117651714A (zh) 2024-03-05
WO2022225921A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
Yu et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
SA520420526B1 (ar) Caix، بروتينات ربط متعددة النوعية تستهدف أوano1،أو ميسوثيلين، أوtrop2،أوcea، أو كلاودين-18.2
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
Bühler et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
MY205758A (en) Anti-nkg2a antibodies and uses thereof
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
JP2016521692A5 (cg-RX-API-DMAC7.html)
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
PH12022553167A1 (en) Agonistic cd28 antigen binding molecules targeting her2
HRP20200272T1 (hr) Kombinirana terapija za imunocitokine varijante il-2 usmjerene na tumor i protutijela protiv humanog pd-l1
EA201890805A1 (ru) Биспецифические антитела против cd3*cd19
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
JOP20200161B1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
EA201300470A1 (ru) Антитела
ZA202401043B (en) Antigen-binding polypeptide targeting b7h3 and application thereof
MX2023008887A (es) Combinaciones farmaceuticas que comprenden un anticuerpo anti-ly75.
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
RU2015119159A (ru) Антитела к интерлейкину 6 и их применение
Moradi-Kalbolandi et al. Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function
WO2020257789A3 (en) Anti-tim-3 antibodies
EA202191173A1 (ru) Моноклональное антитело, которое специфически связывается с cd20
EA202090864A1 (ru) Моноклональное антитело к il-5r
Fei et al. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma